Anavex Life Sciences Corp.
AVXL
$9.53
-$0.02-0.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.17M | 11.47M | 11.74M | 11.29M | 11.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.57M | 53.31M | 53.05M | 50.65M | 49.00M |
| Operating Income | -53.57M | -53.31M | -53.05M | -50.65M | -49.00M |
| Income Before Tax | -48.29M | -47.27M | -46.62M | -43.13M | -41.59M |
| Income Tax Expenses | -124.00K | -124.00K | -124.00K | -124.00K | -64.00K |
| Earnings from Continuing Operations | -48.17 | -47.14 | -46.49 | -43.00 | -41.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.17M | -47.14M | -46.49M | -43.00M | -41.53M |
| EBIT | -53.57M | -53.31M | -53.05M | -50.65M | -49.00M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.57 | -0.56 | -0.55 | -0.51 | -0.50 |
| Normalized Basic EPS | -0.35 | -0.35 | -0.35 | -0.32 | -0.31 |
| EPS Diluted | -0.57 | -0.56 | -0.55 | -0.51 | -0.50 |
| Normalized Diluted EPS | -0.35 | -0.35 | -0.35 | -0.32 | -0.31 |
| Average Basic Shares Outstanding | 340.06M | 339.21M | 336.60M | 333.87M | 331.05M |
| Average Diluted Shares Outstanding | 340.06M | 339.21M | 336.60M | 333.87M | 331.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |